Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 19, 2026
High-Resolution Spatial Multi-Omics Enables Prognostic Scoring in Intrahepatic CholangiocarcinomaYuzhi Jin, Jie Mei, Jinlin Cheng, et al.
Liver Cancer|August 8, 2024
A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394Shukui Qin, Weijia Fang, Zhenggang Ren, et al.
Eclinicalmedicine|October 3, 2022
S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trialYihebali Chi, Lijie Song, Weili Liu, et al.
Nature Cancer|February 27, 2026
Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trialYang Gao, Jie Li, Hangyu Zhang, et al.
Cell Reports. Medicine|February 2, 2024
A multiomics analysis-assisted deep learning model identifies a macrophage-oriented module as a potential therapeutic target in colorectal cancerXuanwen Bao, Qiong Li, Dong Chen, et al.
Cell Discovery|July 2, 2025
Spatially resolved C1QC<sup>+</sup> macrophage-CD4<sup>+</sup> T cell niche in colorectal cancer microenvironment: implications for immunotherapy responseHangyu Zhang, Libing Hong, Zhen Dong, et al.
Cancer Immunology Research|May 23, 2022
Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing-Assisted Multiomics AnalysisXuanwen Bao, Qiong Li, Jinzhang Chen, et al.
Signal Transduction and Targeted Therapy|September 19, 2024
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trialJiujie Cui, Shukui Qin, Yuhong Zhou, et al.
Liver Cancer|March 6, 2023
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 TrialZhenggang Ren, Michel Ducreux, Ghassan K Abou-Alfa, et al.
The Lancet. Gastroenterology & Hepatology|May 10, 2021
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialShukui Qin, Qiu Li, Shanzhi Gu, et al.
Pageof 13